Redwing57 said...
I just received this link in an email from Us TOO. This will take you to the full text version of the article. It is certainly pertinent to those reading this thread. I don't recall if this was already discussed on the forum, as it was published in March 2018. Presented for information; read and do with it what you will.
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
[Edit: Note that this is a retrospective study, so has some inherent risk of selection bias and so on. Just something to keep in mind.
More edit: the EBRT doses are low by today's standards, and the follow up period is short. I'm not very convinced by the results presented. Of course BT is a great way to boost the local radiation dose if the externally applied radiation is low, and that would give misleading preference to EBRT+BT in this particular retrospective study. This is a marginally useful analysis, but it is unusual in the amount of G9-10 cases involved. I don't know... upon reflection this may be more misleading than helpful. Again, as always, caveat emptor....]
(A related item, reference my comments above from page 6 of this thread.)
This link just came in my urotoday email. It's an interesting interview regarding this study with a U of Michigan doctor. Nothing too new, but he does clearly state some things we occasionally discuss on the forum.
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer - Daniel SprattA couple of comments I found interesting (time stamp for beginning of comments):
5:00 - Multi-modality outcome statistics can be skewed by patient selection, since it requires a healthier patient to be eligible for the required anesthesia. Similar to surgery pre-selecting for healthier patients (discussed around 8:00).
11:00 A brachy boost improves biochemical recurrence-free survival, while also increasing the risk 2-3 fold of severe bowel or genital-urinary side effects.
12:00 - if extraprostatic extension exists, prefers dose-escalated EBRT+ADT. (Multi-modality's brachy boost only is effective within the treatment field, basically within the prostate). The combo's lower EBRT field wouldn't be as effective away from the very localized brachy boost field.